Literature DB >> 3754487

Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission.

W G Harker, D Bauer, B B Etiz, R A Newman, B I Sikic.   

Abstract

The effects of verapamil on the cytotoxicity and accumulation of multiple drugs were studied in a model of pleiotropic resistance generated by doxorubicin (DOX) selection of the human sarcoma cell line MES-SA. The in vitro sensitivity of the DOX-resistant variant (named Dx5), which is 50- to 100-fold resistant to DOX compared to MES-SA, was enhanced approximately 7-fold by verapamil (3 micrograms/ml). In addition, the cytotoxicity of several agents to which the Dx5 line displays cross-resistance, i.e., daunorubicin, dactinomycin, mitoxantrone, and etoposide, was also enhanced 2- to 14-fold by verapamil. These agents share the properties of DNA intercalation and/or interaction with topoisomerase II. In contrast, verapamil did not alter the sensitivity of Dx5 to several other agents to which cross-resistance had been demonstrated, i.e., vincristine, vinblastine, colchicine, mitomycin C, and melphalan; nor did verapamil enhance the cytotoxicity of DOX or other agents against the DOX-sensitive parent, MES-SA. The sensitizing effect of verapamil did not correlate well with its effects on intracellular drug accumulation. [14C]DPX accumulation was increased by 30-40% in Dx5 but not in MES-SA cells in the presence of verapamil. [3H]Vinblastine accumulation was increased by 24-72% in both MES-SA and Dx5 cells in the presence of verapamil, although cytotoxicity of the Vinca alkaloids was not affected. In this human sarcoma model of DOX-selected pleiotropic resistance, verapamil partially reversed the resistance to DOX, as well as four of the nine drugs for which cross-resistance had been demonstrated in Dx5. The potentiation by verapamil of the cytotoxicity of some but not all of these antitumor agents suggests that factors other than altered drug transport may be responsible. The pattern of sensitization, restricted to agents which produce DNA strand scission by interaction with topoisomerase II, suggests that verapamil may be acting to promote the formation or inhibit the repair of such DNA strand breaks.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3754487

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism.

Authors:  Pamela Ann Harvey; Leslie Anne Leinwand
Journal:  Cardiovasc Res       Date:  2015-05-25       Impact factor: 10.787

2.  Enhancement of the cytogenetic efficacy of the antitumor agent bleomycin by the calcium and calmodulin antagonist fendiline.

Authors:  W Scheid; H Traut
Journal:  Experientia       Date:  1988-03-15

3.  Modulation of mitomycin C-induced multidrug resistance in vitro.

Authors:  R T Dorr; J D Liddil
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines.

Authors:  K Häussermann; B Benz; V Gekeler; K Schumacher; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.

Authors:  J H Ahmed; J Godden; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

6.  Correction of altered plasma membrane potentials. A possible mechanism of cyclosporin A and verapamil reversal of pleiotropic drug resistance in neoplasia.

Authors:  B Vayuvegula; L Slater; J Meador; S Gupta
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 7.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 8.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 9.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

10.  Mitomycin C cross-resistance induced by adriamycin in human ovarian cancer cells in vitro.

Authors:  K Mizuno; Y Furuhashi; O Maeda; M Iwata; T Misawa; M Kawai; T Kano; Y Tomoda
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.